Enmetazobactam

Summary

Enmetazobactam (CHEMBL4458276) is an approved small molecule; indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 314.32 Da · C11H14N4O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4458276
Name	Enmetazobactam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	23653540
Molecular formula	C11H14N4O5S
Molecular weight	314.32
InChIKey	HFZITXBUTWITPT-YWVKMMECSA-N

SMILES: C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=C[N+](=N3)C

IUPAC name: (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

Also known as: AAI-101, AAI101, Enmetazobactam, Enmetazobactam component of exblifep, OCID-5090, ENMETAZOBACTAM

Patent coverage: 4 distinct patent families (17 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bacterial infectious disease	1	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03680352	PHASE1	COMPLETED	Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects
NCT03685084	PHASE1	COMPLETED	Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers
NCT03775668	PHASE1	COMPLETED	Single Dose Mass Balance Study With C14 - Labeled AAI101 in Healthy Male Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).